|Bid||74.00 x 800|
|Ask||74.05 x 800|
|Day's Range||73.58 - 74.59|
|52 Week Range||59.78 - 80.49|
|Beta (5Y Monthly)||1.01|
|PE Ratio (TTM)||14.59|
|Earnings Date||Jan 31, 2023 - Feb 06, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||78.33|
Subscribe to Yahoo Finance Plus to view Fair Value for HOLX
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
MARLBOROUGH, Mass., November 25, 2022--Hologic, Inc. (Nasdaq: HOLX) will exhibit its extensive portfolio of breast and skeletal health products at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec. 1. Among the full suite of breast biopsy and surgery solutions will be Hologic’s Affirm® Contrast Biopsy software, which will be on display for the first time since becoming commercially available in the United States.
MARLBOROUGH, Mass., November 22, 2022--Hologic to Webcast Presentation at the 5th Annual Evercore ISI HealthCONx Conference